AI assistant
Sending…
Protalix BioTherapeutics, Inc. — Director's Dealing 2012
May 4, 2012
33807_dirs_2012-05-04_17d31e5a-8b3b-46b3-a296-8ed4f3838887.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2012-05-02
Reporting Person: Shaaltiel Yoseph (Director, Executive VP, R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-05-02 | Common Stock | S | 300000 | $7.13 | Disposed | 463754 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
More from Protalix BioTherapeutics, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
May 13
Major Shareholding Notification
2026
Mar 30
Regulatory Filings
2026
Feb 11
Regulatory Filings
2026
Jan 30
Regulatory Filings
2026
Jan 5
Director's Dealing
2025
Dec 23
Director's Dealing
2025
Nov 19
Interim / Quarterly Report
2025
Nov 13